Skip to product information
1 of 1

VEGF165 Recombinant Rabbit mAb (SDT-3855-2)

VEGF165 Recombinant Rabbit mAb (SDT-3855-2)

Catalog Number: S0B3736 Application: CLIA, Sandwich ELISA Reactivity: Hu, Ms Conjugation: Unconjugated Brand: Starter
Price:
Regular price $835 USD
Regular price Sale price $835 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen VEGF-A
Synonyms Vascular endothelial growth factor A, long form; L-VEGF; Vascular permeability factor (VPF); VEGF; VEGFA
Immunogen Recombinant Protein
Clone Number SDT-3855-2
Antibody Type Recombinant mAb
Isotype IgG
Application CLIA, Sandwich ELISA
Reactivity Hu, Ms
Predicted Reactivity Rt
Cross Reactivity

It shows good reactivity with VEGF121 and no cross reactivity against Human TNF-α.

Purification Protein A
Concentration 2 mg/ml
Purity >95% by HPLC
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt, 2 to 8 °C as supplied

Background

Vascular Endothelial Growth Factor A (VEGFA) is a pivotal biomarker in clinical diagnosis, primarily valued for its central role in angiogenesis and disease progression. As a key regulator of new blood vessel formation, its expression is frequently dysregulated in numerous pathologies, especially solid tumors.

In oncology, elevated VEGFA levels in serum or tumor tissues strongly correlate with tumor growth, metastasis, and poor prognosis, making it a critical prognostic indicator. For example, in non-small cell lung cancer, VEGFA expression helps predict disease progression and assess patient outcomes. Beyond diagnosis, it serves as a predictive biomarker for anti-angiogenic therapies, such as bevacizumab, enabling personalized treatment strategies.

Moreover, VEGFA’s diagnostic significance extends to non-neoplastic conditions, including cardiovascular diseases, diabetic retinopathy, and inflammatory disorders, where aberrant angiogenesis contributes to pathogenesis. Its detection, via immunohistochemistry or liquid biopsies, offers a minimally invasive means of disease monitoring. In summary, VEGFA is an indispensable tool in clinical diagnostics, linking disease detection, prognosis, and therapeutic guidance.

Picture

Paired Recommendations